Skip to main content
Top
Published in: Journal of Neurology 11/2017

01-11-2017 | Original Communication

‘Timed up and go’ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis

Authors: Lorena Lorefice, G. Coghe, G. Fenu, M. Porta, G. Pilloni, J. Frau, F. Corona, V. Sechi, M. A. Barracciu, M. G. Marrosu, M. Pau, E. Cocco

Published in: Journal of Neurology | Issue 11/2017

Login to get access

Abstract

Motor and cognitive disabilities are related to brain atrophy in multiple sclerosis (MS). ‘Timed up and go’ (TUG) has been recently tested in MS as functional mobility test, as it is able to evaluate ambulation/coordination-related tasks, as well as cognitive function related to mobility. The objective of this study is to evaluate the relationship between brain volumes and TUG performances. Inclusion criteria were a diagnosis of MS and the ability to walk at least 20 m. TUG was performed using a wearable inertial sensor. Times and velocities of TUG sub-phases were calculated by processing trunk acceleration data. Patients underwent to a brain MRI, and volumes of whole brain, white matter (WM), grey matter (GM), and cortical GM (C) were estimated with SIENAX. Sixty patients were enrolled. Mean age was 41.5 ± 11.6 years and mean EDSS 2.3 ± 1.2. Total TUG duration was correlated to lower WM (ρ = 0.358, p = 0.005) and GM (ρ = 0.309, p = 0.017) volumes. A stronger association with lower GM volume was observed for intermediate (ρ = 0.427, p = 0.001) and final turning (ρ = 0.390, p = 0.002). TUG is a useful tool in a clinical setting as it can not only evaluate patients’ disability in terms of impaired functional mobility, but also estimate pathological features, such as grey atrophy.
Literature
1.
go back to reference Lucchinetti C, Brück W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed Lucchinetti C, Brück W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed
2.
go back to reference Bielekova B, Kadom N, Fisher E et al (2005) MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 65:1071–1076CrossRefPubMed Bielekova B, Kadom N, Fisher E et al (2005) MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 65:1071–1076CrossRefPubMed
3.
go back to reference Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(278–286):3 Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(278–286):3
4.
go back to reference Cocco E, Sardu C, Spinicci G et al (2015) Influence of treatments in multiple sclerosis disability: a cohort study. Mult Scler 21(4):433–441CrossRefPubMed Cocco E, Sardu C, Spinicci G et al (2015) Influence of treatments in multiple sclerosis disability: a cohort study. Mult Scler 21(4):433–441CrossRefPubMed
5.
go back to reference Banwell B, Giovannoni G, Hawkes C et al (2013) Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord 2:65–67CrossRefPubMed Banwell B, Giovannoni G, Hawkes C et al (2013) Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord 2:65–67CrossRefPubMed
6.
go back to reference Haider L, Zrzavy T, Hametner S et al (2016) The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 139(Pt 3):807–815CrossRefPubMedPubMedCentral Haider L, Zrzavy T, Hametner S et al (2016) The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 139(Pt 3):807–815CrossRefPubMedPubMedCentral
7.
go back to reference De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147–156CrossRefPubMed De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147–156CrossRefPubMed
8.
9.
go back to reference Kalkers NF, Ameziane N, Bot JC et al (2002) Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59(10):1572–1576CrossRefPubMed Kalkers NF, Ameziane N, Bot JC et al (2002) Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59(10):1572–1576CrossRefPubMed
10.
go back to reference Zwibel HL (2009) Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 26(12):1043–1057CrossRefPubMed Zwibel HL (2009) Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 26(12):1043–1057CrossRefPubMed
11.
go back to reference Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148CrossRefPubMed Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148CrossRefPubMed
12.
go back to reference Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice L, Marrosu MG, Cocco E (2017) Are static and functional balance abilities related in individuals with Multiple Sclerosis? Mult Scler Relat Disord 15:1–6CrossRefPubMed Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice L, Marrosu MG, Cocco E (2017) Are static and functional balance abilities related in individuals with Multiple Sclerosis? Mult Scler Relat Disord 15:1–6CrossRefPubMed
13.
go back to reference Sebastiao E, Sandroff B, Learmonth YC et al (2016) Validity of the timed up and go test as a measure of functional mobility in persons with multiple sclerosis. Arch Phys Med Rehabil 97:1072–1077CrossRefPubMed Sebastiao E, Sandroff B, Learmonth YC et al (2016) Validity of the timed up and go test as a measure of functional mobility in persons with multiple sclerosis. Arch Phys Med Rehabil 97:1072–1077CrossRefPubMed
14.
go back to reference Allali G, Laidet M, Assal F (2012) Adapted timed up and go: a rapid clinical test to assess gait and cognition in multiple sclerosis. Eur Neurol 67:116–120CrossRefPubMed Allali G, Laidet M, Assal F (2012) Adapted timed up and go: a rapid clinical test to assess gait and cognition in multiple sclerosis. Eur Neurol 67:116–120CrossRefPubMed
15.
go back to reference Charil A, Dagher A, Lerch JP et al (2007) Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 34:509–517CrossRefPubMed Charil A, Dagher A, Lerch JP et al (2007) Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 34:509–517CrossRefPubMed
16.
go back to reference Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral
17.
go back to reference Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed
18.
go back to reference Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17(1):479–489CrossRefPubMed Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17(1):479–489CrossRefPubMed
19.
go back to reference Rocca MA, Battaglini M, Benedict RH et al (2017) Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88(4):403–413CrossRefPubMed Rocca MA, Battaglini M, Benedict RH et al (2017) Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88(4):403–413CrossRefPubMed
20.
go back to reference Martin CL, Phillips BA, Kilpatrick TJ et al (2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12(5):620–628CrossRefPubMed Martin CL, Phillips BA, Kilpatrick TJ et al (2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12(5):620–628CrossRefPubMed
21.
go back to reference Grothe M, Lotze M, Langner S et al (2016) The role of global and regional gray matter volume decrease in multiple sclerosis. J Neurol 263(6):1137–1145CrossRefPubMed Grothe M, Lotze M, Langner S et al (2016) The role of global and regional gray matter volume decrease in multiple sclerosis. J Neurol 263(6):1137–1145CrossRefPubMed
22.
go back to reference Fragoso YD, Wille PR, Abreu M et al (2017) Correlation of clinical findings and brain volume data in multiple sclerosis. J Clin Neurosci 44:155–157CrossRefPubMed Fragoso YD, Wille PR, Abreu M et al (2017) Correlation of clinical findings and brain volume data in multiple sclerosis. J Clin Neurosci 44:155–157CrossRefPubMed
Metadata
Title
‘Timed up and go’ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis
Authors
Lorena Lorefice
G. Coghe
G. Fenu
M. Porta
G. Pilloni
J. Frau
F. Corona
V. Sechi
M. A. Barracciu
M. G. Marrosu
M. Pau
E. Cocco
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 11/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8612-y

Other articles of this Issue 11/2017

Journal of Neurology 11/2017 Go to the issue